Awake serial intralesional steroid injections without surgery as a novel targeted treatment for idiopathic subglottic stenosis
Awake serial intralesional steroid injections without surgery as a novel targeted treatment for idiopathic subglottic stenosis
复制标题
DOI：
10.1002/lary.26874
复制
发表时间：
2018-03-01
期刊：
影响因子：
2.6
通讯作者：
Paddle, Paul
中科院分区：
文献类型：
--
作者：
Franco, Ramon A., Jr.;Husain, Inna;Paddle, Paul
Objectives/HypothesisThe fibrotic/erythematous appearance of the subglottis in idiopathic subglottic stenosis (iSGS) hints that it might respond to repeated intralesional steroid treatment similar to keloids.Study DesignRetrospective cohort study.MethodsThirteen iSGS subjects (six treated in-office with serial intralesional steroid injections [SILSI] versus seven treated endoscopically in the operating room [OR] followed by awake SILSI) between October 2011 and April 2017. Forced spirometry was performed before injections and at each follow-up visit (peak expiratory flow [%PEF] and peak inspiratory flow). Steroids were injected via transcricothyroid or transnasal routes. Injections were grouped into rounds of four to six injections separated by 3 to 5 weeks.ResultsThirteen subjects with a mean follow-up of 3 years (3.3 years for SILSI and 2.7 years for OR). Awake-only SILSI subjects had a mean improvement/round of 23.1% %PEF (range, 65.4%-88.6%), whereas the OR-treated subjects had a mean %PEF improvement/round of 25.1% (range, 57.4%-82.5%). Both groups had improved breathing, and the improvements were statistically equal (P=.569). SILSI subjects underwent 5.3 injections/round in 1.3 rounds, whereas OR subjects had 5.9 injections/round over 2.1 rounds. Statistically significant improvement was seen in %PEF for both groups (SILSI P=.007, OR P=.002). Overall, SILSI achieved sustained %PEF above 80% in 83% (5/6) and OR+SILSI 86% (6/7).ConclusionsSILSI in the awake outpatient setting can improve the airway caliber in iSGS and is equivalent to endoscopic OR treatment. We believe iSGS can be viewed as a chronic scarring/inflammatory condition that can benefit from steroid scar-modification therapy.Level of Evidence4. Laryngoscope, 128:610-617, 2018
